Cargando…
Polysaccharides Extracted from Rhizoma Pleionis Have Antitumor Properties In Vitro and in an H22 Mouse Hepatoma Ascites Model In Vivo
Malignant ascites is a highly severe and intractable complication of advanced or recurrent malignant tumors that is often immunotherapy-resistant. Rhizoma Pleionis is widely used in traditional medicine as an antimicrobial and anticancer agent, but its effectiveness in treating malignant ascites is...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983843/ https://www.ncbi.nlm.nih.gov/pubmed/29735884 http://dx.doi.org/10.3390/ijms19051386 |
_version_ | 1783328512599392256 |
---|---|
author | Fang, Yukun Ning, Anhong Li, Sha Zhou, Shaozheng Liu, Lei Joseph, Thomson Patrick Zhong, Mintao Jiao, Jilong Zhang, Wei Shi, Yonghui Zhang, Meishan Huang, Min |
author_facet | Fang, Yukun Ning, Anhong Li, Sha Zhou, Shaozheng Liu, Lei Joseph, Thomson Patrick Zhong, Mintao Jiao, Jilong Zhang, Wei Shi, Yonghui Zhang, Meishan Huang, Min |
author_sort | Fang, Yukun |
collection | PubMed |
description | Malignant ascites is a highly severe and intractable complication of advanced or recurrent malignant tumors that is often immunotherapy-resistant. Rhizoma Pleionis is widely used in traditional medicine as an antimicrobial and anticancer agent, but its effectiveness in treating malignant ascites is unclear. In the current study, we investigated the effect of polysaccharides isolated from Rhizoma Pleionis (PRP) on murine hepatocarcinoma H22 cells in an ascites model. We have found that the main components of PRP, that presented a relative molecular weight of 383.57 kDa, were mannose and glucose. We also found that PRP reduced the occurrence of abdominal ascites and increased survival in our mouse model. An immune response in the ascites tumor model was observed by performing a lymphocytes proliferation experiment and an E-rosette test. The ratios of CD8+ cytotoxic T cells and NK cells in the spleen were examined by flow cytometry, and the mRNA expression of Foxp3+in CD4(+)CD25(+) (T regulatory Tregs) was measured by RT-PCR (reverse transcription-polymerase chain reaction). The levels of the cytokines TNF-α (tumor necrosis factor), VEGF (vascular endothelial growth factor), IL-2 (interleukin), and IFN-γ (interferon) in the serum and ascites supernatants were measured by ELISA. The expression of Foxp3 and Stat3 in peritoneal cells in the mouse model was measured by immunocytochemistry. The results indicated that PRP increased H22 tumor cell apoptosis in vivo by activating and enhancing the immune response. Furthermore, the effects of PRP on the proliferation of H22 cells were assessed by the CCK8 assay, Hoechest 33258, and TUNEL staining in vitro. We found that PRP suppressed the proliferation of H22 tumor cells but had no effect on BRL (Big rat liver) -3A rat hepatoma normal cells in vitro. Next, we investigated the underlying immunological mechanism by which PRP inhibits malignant ascites. PRP induced tumor cell apoptosis by inhibiting the Jak1–Stat3 pathway and by activating Caspase-3 and Caspase-8 to increase the Bax/Bcl-2 ratio. Collectively, our results indicate that PRP exhibits significant antitumor properties in H22 cells in vivo and in vitro, indicating that PRP may be used as a new therapeutic drug for cancer treatment. |
format | Online Article Text |
id | pubmed-5983843 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-59838432018-06-05 Polysaccharides Extracted from Rhizoma Pleionis Have Antitumor Properties In Vitro and in an H22 Mouse Hepatoma Ascites Model In Vivo Fang, Yukun Ning, Anhong Li, Sha Zhou, Shaozheng Liu, Lei Joseph, Thomson Patrick Zhong, Mintao Jiao, Jilong Zhang, Wei Shi, Yonghui Zhang, Meishan Huang, Min Int J Mol Sci Article Malignant ascites is a highly severe and intractable complication of advanced or recurrent malignant tumors that is often immunotherapy-resistant. Rhizoma Pleionis is widely used in traditional medicine as an antimicrobial and anticancer agent, but its effectiveness in treating malignant ascites is unclear. In the current study, we investigated the effect of polysaccharides isolated from Rhizoma Pleionis (PRP) on murine hepatocarcinoma H22 cells in an ascites model. We have found that the main components of PRP, that presented a relative molecular weight of 383.57 kDa, were mannose and glucose. We also found that PRP reduced the occurrence of abdominal ascites and increased survival in our mouse model. An immune response in the ascites tumor model was observed by performing a lymphocytes proliferation experiment and an E-rosette test. The ratios of CD8+ cytotoxic T cells and NK cells in the spleen were examined by flow cytometry, and the mRNA expression of Foxp3+in CD4(+)CD25(+) (T regulatory Tregs) was measured by RT-PCR (reverse transcription-polymerase chain reaction). The levels of the cytokines TNF-α (tumor necrosis factor), VEGF (vascular endothelial growth factor), IL-2 (interleukin), and IFN-γ (interferon) in the serum and ascites supernatants were measured by ELISA. The expression of Foxp3 and Stat3 in peritoneal cells in the mouse model was measured by immunocytochemistry. The results indicated that PRP increased H22 tumor cell apoptosis in vivo by activating and enhancing the immune response. Furthermore, the effects of PRP on the proliferation of H22 cells were assessed by the CCK8 assay, Hoechest 33258, and TUNEL staining in vitro. We found that PRP suppressed the proliferation of H22 tumor cells but had no effect on BRL (Big rat liver) -3A rat hepatoma normal cells in vitro. Next, we investigated the underlying immunological mechanism by which PRP inhibits malignant ascites. PRP induced tumor cell apoptosis by inhibiting the Jak1–Stat3 pathway and by activating Caspase-3 and Caspase-8 to increase the Bax/Bcl-2 ratio. Collectively, our results indicate that PRP exhibits significant antitumor properties in H22 cells in vivo and in vitro, indicating that PRP may be used as a new therapeutic drug for cancer treatment. MDPI 2018-05-07 /pmc/articles/PMC5983843/ /pubmed/29735884 http://dx.doi.org/10.3390/ijms19051386 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fang, Yukun Ning, Anhong Li, Sha Zhou, Shaozheng Liu, Lei Joseph, Thomson Patrick Zhong, Mintao Jiao, Jilong Zhang, Wei Shi, Yonghui Zhang, Meishan Huang, Min Polysaccharides Extracted from Rhizoma Pleionis Have Antitumor Properties In Vitro and in an H22 Mouse Hepatoma Ascites Model In Vivo |
title | Polysaccharides Extracted from Rhizoma Pleionis Have Antitumor Properties In Vitro and in an H22 Mouse Hepatoma Ascites Model In Vivo |
title_full | Polysaccharides Extracted from Rhizoma Pleionis Have Antitumor Properties In Vitro and in an H22 Mouse Hepatoma Ascites Model In Vivo |
title_fullStr | Polysaccharides Extracted from Rhizoma Pleionis Have Antitumor Properties In Vitro and in an H22 Mouse Hepatoma Ascites Model In Vivo |
title_full_unstemmed | Polysaccharides Extracted from Rhizoma Pleionis Have Antitumor Properties In Vitro and in an H22 Mouse Hepatoma Ascites Model In Vivo |
title_short | Polysaccharides Extracted from Rhizoma Pleionis Have Antitumor Properties In Vitro and in an H22 Mouse Hepatoma Ascites Model In Vivo |
title_sort | polysaccharides extracted from rhizoma pleionis have antitumor properties in vitro and in an h22 mouse hepatoma ascites model in vivo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983843/ https://www.ncbi.nlm.nih.gov/pubmed/29735884 http://dx.doi.org/10.3390/ijms19051386 |
work_keys_str_mv | AT fangyukun polysaccharidesextractedfromrhizomapleionishaveantitumorpropertiesinvitroandinanh22mousehepatomaascitesmodelinvivo AT ninganhong polysaccharidesextractedfromrhizomapleionishaveantitumorpropertiesinvitroandinanh22mousehepatomaascitesmodelinvivo AT lisha polysaccharidesextractedfromrhizomapleionishaveantitumorpropertiesinvitroandinanh22mousehepatomaascitesmodelinvivo AT zhoushaozheng polysaccharidesextractedfromrhizomapleionishaveantitumorpropertiesinvitroandinanh22mousehepatomaascitesmodelinvivo AT liulei polysaccharidesextractedfromrhizomapleionishaveantitumorpropertiesinvitroandinanh22mousehepatomaascitesmodelinvivo AT josephthomsonpatrick polysaccharidesextractedfromrhizomapleionishaveantitumorpropertiesinvitroandinanh22mousehepatomaascitesmodelinvivo AT zhongmintao polysaccharidesextractedfromrhizomapleionishaveantitumorpropertiesinvitroandinanh22mousehepatomaascitesmodelinvivo AT jiaojilong polysaccharidesextractedfromrhizomapleionishaveantitumorpropertiesinvitroandinanh22mousehepatomaascitesmodelinvivo AT zhangwei polysaccharidesextractedfromrhizomapleionishaveantitumorpropertiesinvitroandinanh22mousehepatomaascitesmodelinvivo AT shiyonghui polysaccharidesextractedfromrhizomapleionishaveantitumorpropertiesinvitroandinanh22mousehepatomaascitesmodelinvivo AT zhangmeishan polysaccharidesextractedfromrhizomapleionishaveantitumorpropertiesinvitroandinanh22mousehepatomaascitesmodelinvivo AT huangmin polysaccharidesextractedfromrhizomapleionishaveantitumorpropertiesinvitroandinanh22mousehepatomaascitesmodelinvivo |